Emmanuel S. Antonarakis

Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (70)

Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS and PFS. The associations of PSMA+ CTC enumeration with overall survival (OS) and progression-free survival (PFS) were explored using the proportional hazard model. A) The median OS in months for CTC=0 (reference), CTC+ PSMA-CTC, CTC+ PSMA+CTC but heterogeneous (

Year:

2025

Comparison of the frequencies of additional molecular features between non-castrate (NC) and castrate (C) samples in ATMm, BRCA2m, HRDother, and HRP groups. The significant differences between the two groups are highlighted (red box).

Year:

2025

Waterfall plots depicting A) the proportion of men achieving a 50% or greater PSA decline from baseline, confirmed with a subsequent value (confirmed PSA50) and B) best overall objective radiographic responses among response evaluable subjects at baseline, by RECIST 1.1 criteria.

Year:

2025

A. Overall Survival outcomes and B. Progression Free Survival outcomes utilizing multivariate analysis for PSMA positive CTCs, adjusting on prior treatment, risk score, CTC enumeration, comparting 3 CTC + groups with the reference group being CTC 0.

Year:

2025

Comparison of CTC enumeration and PSMA+ CTC expression in 57 baseline and paired progression samples from the PROPHECY study. All the CTC parameters (mean, median, and range) were represent in CTC/mL.

Year:

2025

The roles of nucleoplasm-residing nucleoporins (NUP) in solid tumors, including prostate cancer, remain unknown. In this study, we reveal the clinical significance and mechanistic role of the off-pore NUP, soluble POM121 (sPOM121), as a crucial transcriptional regulator that enhances the aggressiveness of metastatic prostate cancer. Using orthogonal methodologies in human samples, sPOM121 was identified as the predominantly expressed nucleoplasmic NUP in prostate cancer. Unbiased proteomic and epigenomic studies demonstrate that sPOM121, through its C-terminus, interacts with the chromatin remodeler SMARCA5 at gene promoter sites and localizes at nuclear condensates, reprogramming gene expression. Indeed, sPOM121 regulates a distinct oncogenic gene network, including β-catenin, leading to prostate cancer progression and immune evasion. Importantly, targeting the sPOM121/β-catenin axis in patient-derived preclinical and syngeneic mouse models halts prostate cancer aggressiveness and enhances antitumor immunity. Taken together, these findings reveal previously unknown actionable reprogramming functions of off-pore NUPs in solid tumors. Significance: This study uncovers how oncogenic signaling programs are transcriptionally heightened by the NUP sPOM121 in metastatic prostate cancer. Localization of sPOM121 at active transcriptional nuclear condensates propels disease progression and immune evasion, offering novel anticancer therapeutic opportunities.

Year:

2025

Purpose: Homologous recombination/DNA damage repair (HRR) alterations (HRRalt) are found in around 30% of patients with advanced prostate cancer and have been associated with worse prognosis in the metastatic castrate-resistant setting. However, there are limited data with regard to their association with outcomes of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Experimental Design: This study used a de-identified nationwide (U.S.-based) prostate cancer clinico-genomic database. Patients with de novo mHSPC treated with androgen deprivation therapy intensification with either an androgen receptor pathway inhibitor (ARPI) or a taxane who underwent tissue biopsy within 90 days of mHSPC diagnosis were included. Time to castrate resistance (TTCR) and overall survival (OS) were compared between patients with non-altered HRR and those with HRRalt in any of 14 prespecified genes per the olaparib monotherapy FDA label. TTCR and OS indexed from mHSPC diagnosis were evaluated with Cox proportional hazard models adjusted for baseline prognostic factors. Results: Of 637 eligible patients included in our analysis, 181 harbored HRRalt (28.4%). Compared with patients with non-altered HRR, those with HRRalt had less favorable TTCR when treated with an ARPI [adjusted HR (aHR) = 1.58; 95% confidence interval (CI), 1.17–2.14] or a taxane (aHR = 1.77; 95% CI, 1.3–2.4). Additionally, OS was directionally less favorable in patients with HRRalt (ARPI: aHR = 1.12; 95% CI, 0.80–1.57 and taxane: aHR = 1.23; 95% CI, 0.88–1.72). Conclusions: To date, this is the largest real-world natural history study evaluating the association of HRRalt with outcomes in the mHSPC setting. These data may inform future clinical trial design and counseling of these patients. See related commentary by Graham and Yu, p. 4001

Year:

2025

Outcomes on ARPI or taxane by CDK12alt status. Outcomes for CDK12alt vs. no CDK12alt are shown on ADT + ARPI for (A) TTCRPC and (C) OS. Outcomes for CDK12alt vs. no CDK12alt are shown on ADT + taxane for (B) TTCR and (D) OS. Abbreviations: aHR, adjusted hazard ratio; alt, alteration; ARPI, androgen receptor pathway inhibitor; CI, confidence interval; CRPC, castrate-resistant prostate cancer; doce, docetaxel; TTCR, time to castrate-resistance; OS, overall survival.

Year:

2025

Outcomes on ARPI or taxane by ATMalt status. Outcomes for ATMalt vs. no ATMalt are shown on ADT + ARPI for (A) TTCR and (C) OS. Outcomes for ATMalt vs. no ATMalt are shown on ADT + taxane for (B) TTCR and (D) OS. Abbreviations: aHR, adjusted hazard ratio; alt, alteration; ARPI, androgen receptor pathway inhibitor; CI, confidence interval; CRPC, castrate-resistant prostate cancer; doce, docetaxel; TTCR, time to castrate-resistance; OS, overall survival.

Year:

2025

Outcomes on ARPI or taxane by BRCAalt status. Outcomes for BRCAalt vs. no BRCAalt are shown on ADT + ARPI for (A) TTCR and (C) OS. Outcomes for BRCAalt vs. no BRCAalt are shown on ADT + taxane for (B) TTCR and (D) OS. Abbreviations: aHR, adjusted hazard ratio; alt, alteration; ARPI, androgen receptor pathway inhibitor; CI, confidence interval; CRPC, castrate-resistant prostate cancer; doce, docetaxel; TTCR, time to castrate-resistance; OS, overall survival.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (86)

Yvette Soignier

University of Minnesota Twin Cities

UNITED STATES
View details

Aditya Bagrodia

University of Texas Southwestern

UNITED STATES
View details

Andrew Armstrong

Professor

Duke Cancer Institute

UNITED STATES
View details

Ulka Vaishampayan

Professor

University of Michigan

UNITED STATES
View details

Karim Fizazi

Université Paris-Saclay

FRANCE
View details

Oliver Sartor

Tulane University School of Medicine

UNITED STATES
View details

Ginger Milne

Professor with Tenure

Vanderbilt University Medical Center

UNITED STATES
View details

Pedro Barata

Associate Professor of Medicine

University Hospitals Seidman Cancer Center

UNITED STATES
View details

Laura Kotz

University of Minnesota Twin Cities

UNITED STATES
View details

John Lozada

University of Rochester Medical Center

UNITED STATES
View details

Benedito A. Carneiro

-

UNITED STATES
View details

George Sledge

-

UNITED STATES
View details

Philippa Kennedy

Faculty, Assistant Professor

University of Minnesota

UNITED STATES
View details

Phillip Palmbos

Assistant Professor

University of Michigan Hospital

UNITED STATES
View details

Channing Paller

Johns Hopkins University

UNITED STATES
View details

Natalie Reizine

Assistant Professor

University of Chicago

UNITED STATES
View details

Arul M Chinnaiyan

University of Michigan

UNITED STATES
View details

Akhilesh Kumar

Faculty, Assistant Professor

University of Minnesota

UNITED STATES
View details

Donald P. McDonnell

Duke University School of Medicine

UNITED STATES
View details

Scott Tagawa

Weill Cornell Medicine

UNITED STATES
View details

Emil Lou

University of Minnesota

UNITED STATES
View details

Ari VanderWalde

Global Head of Clinical Trials

-

UNITED STATES
View details

Dang Nguyen

Faculty, Assistant Professor

University of Minnesota

UNITED STATES
View details

Young Whang

University of North Carolina at Chapel Hill School of Medicine

UNITED STATES
View details

Eugene Shenderov

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Kent Mouw

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Haojie Huang

Professor

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Matthew Rettig

Professor

University of California, Los Angeles

UNITED STATES
View details

Justin Hwang

Associate Professor

University of Minnesota

UNITED STATES
View details

Chadi Hage Chehade

Huntsman Cancer Institute

UNITED STATES
View details

AKASH ROY

Medical University of South Carolina

UNITED STATES
View details

Brandon Mahal

University of Miami Hospital

UNITED STATES
View details

Siddhartha Yadav

Associate Professor of Oncology

Mayo Clinic

UNITED STATES
View details

Veronica Rodriguez-Bravo

Associate Professor

Mayo Clinic

UNITED STATES
View details

Shijia Zhu

Assistant Professor

University of Minnesota

UNITED STATES
View details

Catherine Marshall

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Jinhua Wang

professor

University of Minnesota System

UNITED STATES
View details

Umang Swami

University of Utah

UNITED STATES
View details

Rohan Garje

Clinical Associate professor

Iowa State University

UNITED STATES
View details

Daniel J. George

Professor

Duke University

UNITED STATES
View details

Elisabeth I. Heath

Wayne State University School of Medicine

UNITED STATES
View details

Maha Hussain

Professor

Northwestern University

UNITED STATES
View details

Ryan D Stephenson

Assistant Professor of Medicine

Rutgers Cancer Institute of New Jersey

UNITED STATES
View details

Zeynep Irem Ozay

University of Utah Health Huntsman Cancer Institute

UNITED STATES
View details

Frank Cichocki

Assistant Professor

University of Minnesota

UNITED STATES
View details

Susan Halabi

Duke University

UNITED STATES
View details

Heloisa Soares

Associate Professor

Huntsman Cancer Institute

UNITED STATES
View details

Emily Egusa

University of California, San Francisco

UNITED STATES
View details

Josep Domingo-Domenech

Professor

Mayo Clinic

UNITED STATES
View details

Haidong Dong

Professor/Consultant

Mayo Clinic Rochester

UNITED STATES
View details

Jacob Orme

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Scott M Dehm

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Martin Felices

Associate Professor

University of Minnesota

UNITED STATES
View details

Xianghua Luo

Professor

University of Minnesota

UNITED STATES
View details

Karen S Sfanos

Johns Hopkins University School of Medicine

UNITED STATES
View details

Christopher J. Hoimes

Duke University

UNITED STATES
View details

John Norris

Associate Research Professor

Duke University

UNITED STATES
View details

Michael Carducci

Vice Chair, Solid Tumor Oncology

Johns Hopkins University

UNITED STATES
View details

Carly Miller

University of Minnesota

UNITED STATES
View details

Jonathan Chou

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Jeffrey S Miller

University of Minnesota System

UNITED STATES
View details

Felix Y. Feng

University of California

UNITED STATES
View details

Mukesh Pandey

Professor of Radiology

Mayo Clinic

UNITED STATES
View details

Angelo De Marzo

Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Sumit Subudhi

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Russell Z. Szmulewitz

Associate Professor

University of Chicago

UNITED STATES
View details

Kevin Kelly

Professor, Associate Director of Research, SKCC

Thomas Jefferson University

UNITED STATES
View details

Charles Nguyen

Assistant Clinical Professor

City Of Hope National Medical Center

UNITED STATES
View details

Megan E.V. Caram

University of Michigan

UNITED STATES
View details

Brent Rose

Associate Professor

UC San Diego Health System

UNITED STATES
View details

Russell K. Pachynski

Washington University School of Medicine

UNITED STATES
View details

Kathleen Storey

Assistant Professor

University of Minnesota

UNITED STATES
View details

Nicholas Zorko

Assistant Professor

University of Minnesota

UNITED STATES
View details

Neeraj Agarwal

Faculty Member

Dana-Farber Cancer Institute

UNITED STATES
View details

David Nanus

Professor of Medicine

Weill Cornell Medicine

UNITED STATES
View details

Daniel P. Petrylak

-

UNITED STATES
View details

Tanya Dorff

Associate Professor

City Of Hope National Medical Center

UNITED STATES
View details

Justin M. Drake

University of Minnesota

UNITED STATES
View details

Rana R. McKay

University of California, San Diego

UNITED STATES
View details

Samuel R. Denmeade

-

UNITED STATES
View details

Dave Hoon

Principal Investigator

The Lundquist Institute

UNITED STATES
View details

Xiaolei Shi

Assistant professor

University of Maryland Medical Center

UNITED STATES
View details

Aditya Pratapa

Assistant Research Professor

Duke University

UNITED STATES
View details

Veerabhadran Baladandayuthapani

Jeremy M.G. Taylor Collegiate Professor of Biostatistics and Chair of Department of Biostatistics

University of Michigan

UNITED STATES
View details

R. Stephanie Huang

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Siyuan Guo

Assistant Professor

Virginia Commonwealth University

UNITED STATES
View details